PRLD Prelude Therapeutics

Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

WILMINGTON, Del., March 01, 2023 (GLOBE NEWSWIRE) -- (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023.

On March 16, at 9:30 a.m. ET, Kris Vaddi, Ph.D., CEO of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat, hosted by Barclays. The company will host one-on-one meetings on March 15 and 16.

About Prelude

Prelude is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Prelude’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a brain penetrant CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

For more information, visit our and follow us on and .

Investor Contact:

Lindsey Trickett

Vice President, Investor Relations

240.543.7970

Media Contact:

Helen Shik

Shik Communications

617.510.4373

 



EN
01/03/2023

Underlying

PRLDPrelude Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Prelude Therapeutics

 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from...

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026 First disclosure of a mutant calreticulin (mCALR) targeted degrader antibody conjugate (DAC) with a novel CDK9 degrader payload JAK2V617F and mCALR are the two primary driver mutations responsible for disease progression and poor prog...

December 6, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and ...

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and CALR-targeted degrader antibody conjugate (DAC) program were both accepted for oral presentations at the American Society of Hematology (ASH) 67th Annual Meeting in December Current cash runway into 20...

November 12, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Announces Strategic Business Update

Prelude Therapeutics Announces Strategic Business Update Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company’s preliminary estimates, and potentially into the third quarter of 2028 if Incyt...

November 4, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte ...

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milesto...

November 4, 2025 1 EN
 PRESS RELEASE
Free
PRLD Prelude Therape...

Prelude Therapeutics Announces Publication of Abstracts for Presentati...

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of two abstracts with preclinical data on the Company’s JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates (DACs) discovery program, both accepted for oral presentation at the American Society of Hematology (ASH) 67th Annu...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch